Bone News and Research

RSS

Wnt signaling pathway plays a role in diabetic retinopathy

A group led by Dr. Jian-xing Ma at The University of Oklahoma Health Sciences Center, Oklahoma City, OK has demonstrated that the Wnt signaling pathway plays a role in diabetic retinopathy.

26 Nov 2009

Scientists offer first genetic proof of new and rational treatment for osteoporosis

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).

26 Nov 2009

Chiropractic treatment for TMJ dysfunction

When most people hear the acronym TMJ, they think of their dentist. But a chiropractor can also give patients the help they need. TMJ stands for the Temporal-Mandibular Joint, which is where your jaw (mandible) contacts/connects with your skull (temporal bone).

26 Nov 2009

Foot ulcers: One of the many challenges of diabetics

Diabetics face many health challenges, and among them is the risk of developing foot ulcers.

25 Nov 2009

Emerging trends that drive the U.S. market for trauma fixation devices

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the nearly $3 billion US market for trauma fixation devices will continue to see rapid growth over the next five years despite the recent economic slowdown. MRG's US Markets for Trauma Devices 2010 report finds that this market will remain highly dynamic over the next five years, with competitors introducing specialized devices in previously underserved segments of the trauma fixation market, fueling market growth.

25 Nov 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

Incyte enters into collaboration and license agreement with Novartis

Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

25 Nov 2009

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Stents that keep weakened and flabby arteries from collapsing have been true life-savers. But after six months, those stents are no longer needed -- once the arteries are strengthened, they become unnecessary. Previously, doctors had no choice but to leave them in place.

25 Nov 2009

$Current, older generation is more prone to hip and pelvic fractures$

Current, older generation is more prone to hip and pelvic fractures

Stover and his partner, Dr. Hobie Summers, use leading edge technologies to treat serious and sometimes life-threatening orthopedic conditions such as pelvic fractures, broken legs, foot and ankle injuries and dislocations. They also treat patients who have experienced multiple traumatic injuries.

24 Nov 2009

Shire submits a MAA for velaglucerase alfa in Europe

Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

24 Nov 2009

DJO's new Moveo XP Rehabilitation Platform granted U.S. patent

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that its Chattanooga division was issued U.S. Patent No. 7597656 for Chattanooga’s new Moveo XP Rehabilitation Platform. The Moveo XP is the first product of its kind, allowing patients who are incapable of supporting full body weight to participate in graded weight-bearing activity at an earlier stage in their physical rehabilitation.

24 Nov 2009

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN) to update the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra(TM), GlaxoSmithKline) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as treatment options for select patients with two types of Non-Hodgkin's Lymphomas.

24 Nov 2009

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. The report illustrates the findings of the first international consensus conference -- Diabetes Surgery Summit (DSS) -- where an international group of more than 50 scientific and medical experts agreed on a set of evidence-based guidelines and definitions that are meant to guide the use and study of gastrointestinal surgery to treat type 2 diabetes. The document is considered to be the foundation of diabetes surgery as a medical discipline of its own.

24 Nov 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Minimally invasive procedure relieves chronic back pain for retired school teacher

Carole Riggs, a retired teacher and school principal, points to her work during one Christmas vacation - bending, twisting and sitting on the floor to create games and teaching aids - as the primary culprit behind many years of back pain.

24 Nov 2009

Researchers find causes for patellofemoral pain syndrome

From professional athletes to weekend warriors, the condition known as "runner's knee" is a painful and potentially debilitating injury suffered by millions of people - although until now, it has been unclear just what causes it.

24 Nov 2009

Custom Spine launches two new innovative spine systems at NASS annual meeting

Custom Spine, a company dedicated to offering advanced spinal solutions, launched two new innovative spine systems at the North American Spine Society's (NASS) annual meeting being held in San Francisco.

24 Nov 2009

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Two separate studies published in the current issue of Cell Transplantation (18:8), - now freely available on-line at http://www.ingentaconnect.com/content/cog/ct - have shown that transplanted human-derived umbilical cord blood (UCB) stem cells transplanted in an animal model had positive therapeutic effects on specific lung and heart disorders the animal models.

24 Nov 2009

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

DGIMED ORTHO's 510(k) submission for Drill and Intramedullary (IM) Nail system receives FDA clearance

DGIMED ORTHO, Inc. announced today that the company has received notification of clearance on its 510(k) submission for the Company’s proprietary Drill and Intramedullary (IM) Nail system.

24 Nov 2009